Charles B. Eaton MD, MS
GIM/FP/GP:
Cardiology:
Eaton MD CB. Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk. Ann Intern Med. 2016;165:JC8. doi: 10.7326/ACPJC-2016-165-2-008
Download citation file:
© 2018
Published: Ann Intern Med. 2016;165(2):JC8.
DOI: 10.7326/ACPJC-2016-165-2-008
Cardiology, Coronary Risk Factors, Dyslipidemia, Hypertension, Nephrology.
Results provided by: